Asciminib monotherapy as frontline treatment of chronic-phase chronic myeloid leukemia: results from the ASCEND studyDavid T Yeung, Timothy P. Hughes, Jake Shortt et al.|Blood|2024Cited by 24
Early and Deep Molecular Responses Achieved with Frontline Asciminib in Chronic Phase CML - Interim Results from ALLG CML13 Ascend-CMLDavid T Yeung, Timothy P. Hughes, Naranie Shanmuganathan et al.|Blood|2022Cited by 4
P720: PROACTIVE DASATINIB DOSE REDUCTION IN THE ALLG CML 12 DIRECT STUDY BASED ON TROUGH LEVELS MINIMISE TOXICITY AND PRESERVE EFFICACYDavid T Yeung, Timothy P. Hughes, Andrew Grigg et al.|HemaSphere|2022Cited by 1